473.78 0.00 (0.00%)
After hours: 5:02PM EDT
|Bid||467.01 x 800|
|Ask||474.08 x 1000|
|Day's Range||467.69 - 482.53|
|52 Week Range||430.24 - 589.32|
|Beta (3Y Monthly)||1.19|
|PE Ratio (TTM)||49.30|
|Earnings Date||Jul 17, 2019 - Jul 22, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||574.38|
Intuitive Surgical is already in 71% of large hospitals, an analyst said Wednesday, so the robotic surgery leader may have to be flexible on its $2 million price tag to keep growing.
Intuitive Surgical (ISRG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investing with IBD is a weekly podcast focused on helping investors learn how to make more money in the stock market by using stock charts to find top stocks.
Every success-minded stock investor desires to sell all top stocks at the top. Alas, every investor is also human. Yet you don't need to be perfect to bag a large chunk of profits from your best stocks. For more than 20 years, the Investor's Corner has published hundreds of articles on the best rules in selling big winning stocks. One of...
Here's a stock story about why an investor sought out some expert advice on a medical technology company, and then totally ignored it.
David Gardner and his guests talk about some of the investments that provided them with their best non-monetary takeaways.
President & CEO of Intuitive Surgical Inc (NASDAQ:ISRG) Gary S Guthart sold 22,636 shares of ISRG on 05/06/2019 at an average price of $501.48 a share.
Intuitive Surgical Inc NASDAQ/NGS:ISRGView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for ISRG with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ISRG totaled $6.93 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
You don't need to go fishing for risky companies to get standout growth. Here are three reliable names that could easily double or triple from here.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you want to know who really controls Intuitive Surgical, Inc. (NASDAQ:ISRG), then you'll have to l...
Want to make money on the stock market? One of the best ways to find good healthcare stocks to buy is by following the best ideas of successful portfolio managers. How do you find them? Well, you could use a mutual fund screener to find top performers. Or, you could do a Google search for mutual funds that gained notoriety in 2018 and buy the fund manager's best ideas. I'm talking about stocks in the top 10 or top 25 holdings. InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe only problem with this solution is that mutual fund holdings aren't real time, so you're usually getting a list of stocks that are stale, dated, and no longer at the top of the fund manager's holdings list or even a holding 4-6 weeks after the end of the quarterly report. This little problem aside, it's still an excellent way to get ideas, even if you ultimately don't pull the trigger. And two of the best-performing categories of mutual funds in 2018 were large-cap growth and healthcare funds. One of these healthcare funds was the T. Rowe Price Health Sciences Fund (MUTF:PRHSX), which had a total return of 1.23% last year, 561 basis points higher than the S&P 500. * 7 Energy Stocks to Buy to Light Up Your Portfolio Trailing the index by a significant amount through the first four months now might be the perfect time to check out its holdings list for healthcare stocks to buy. Healthcare Stocks to Buy: United Health (UNH)Source: Shutterstock UnitedHealth Group (NYSE:UNH) is the fund's number one holding with a weighting of 6.5% as of March 31. For obvious reasons which I'll explain, UNH stock hasn't had a good year to date. It's down over 6%, well behind the 17.5% gain by the S&P 500. UnitedHealth has two distinct businesses: The first provides healthcare plans for a company's employees. That's UnitedHealth. The second, known as Optum, provides health services to individuals, many of them having UnitedHealth healthcare benefits. As the Democratic candidates have come out of the woodwork in 2019, many of them have called for some form of universal healthcare in the U.S., some even suggesting following a single-payer system like the kind found in Canada. The idea of implementing a socialist healthcare plan scared investors. As they wondered whether an entire half of UnitedHealth's business would be wiped out under such a scenario, UNH stock's become kryptonite. However, as I stated in my April 18 article about UNH, investors should consider buying its stock near 52-week lows because investor fears are likely overblown. Since then, it's up 6% through May 1. As healthcare stocks go, UNH is as stable as they come. Intuitive Surgical (ISRG)Source: Jon Fingas via Flickr (Modified)Of all the healthcare stocks in the fund's top 25 holdings, Intuitive Surgical (NASDAQ:ISRG) is probably the healthcare stock I'm most familiar. The second-largest holding in PRHSX, it has a weighting of 5.5%. Like UNH, ISRG hasn't exactly lit up the scoreboard in 2019. It's up 6% year to date. I first recommended ISRG stock in March 2013. Intuitive Surgical's stock price was under pressure due to lawsuits it faced over the company's da Vinci surgical systems. It got so severe that the FDA was looking into whether robotics was a threat to patient safety. As a result, ISRG was down 8.4% over 52 weeks, while the S&P 500 was up 25%, putting shareholders in a very grumpy mood. Here's what I said about its stock at that time:"Intuitive Surgical is a great company that is growing free cash flow at a significant rate. If you own shares already, I'd applaud any pullbacks in its stock. If you don't own any shares, buy some now and then some later if it drops some more. If you don't, you'll be kicking yourself in five years when it's a $1,000 stock." * 10 Cheap Stocks to Buy Now Well, hyperbole aside, it's still an outstanding healthcare stock to own, even at half the price. Pfizer (PFE)Source: Shutterstock I don't know which type of healthcare stock I have a harder time assessing: a big pharma play like Pfizer (NYSE:PFE) or a small biotech stock like Mustang Bio (NASDAQ:BIO). Not being a science guy, the jargon gets a bit tricky. The seventh-largest holding in the fund with a weighting of 2.9%, I picked Pfizer because it's recently added 1.2 million shares, increasing its shareholdings by 16%, the largest addition by shares in the top 25. Clearly, portfolio manager Ziad Bakri sees some serious capital appreciation in its future. I know InvestorPlace's own James Brumley thinks highly of Pfizer's drug pipeline. "Though the headlines and sentiment seem dire, that pessimism is largely rooted in investors' collective view that sees a glass as half-empty rather than half-full," Brumley wrote in April. "Pfizer's got a quietly potent pipeline, though, with a mix of already-approved and new drugs closer to wrapping up clinical trials than many investors might realize."Translation: Pfizer should not be in negative territory given the strength of its portfolio of drugs combined with the momentum in the overall markets. At a 14x price-to-earnings ratio, it's trading at a valuation well below its historical norm. Roche (RHHBY)Source: Images Money via FlickrOf all seven of these healthcare stocks to buy, Roche (OTCMKTS:RHHBY) appears to be the only new position in the fund's top 25 holdings with an initial 664,009 shares bought. Why did Bakri buy into the Swiss pharmaceutical company? That I couldn't tell you. What I do know is that the company is optimistic about 2019. On April 17, Roche upped its outlook for the year due to higher sales expectations in both China and the U.S. This despite downward pricing pressure from President Trump. At the end of 2018, Roche projected its sales growth this year would be low-to-mid-single digits. In its Q1 2019 earnings release April 17, it said it now expects sales to grow by at least mid-single digits with core earnings rising by a similar amount. "We haven't taken any price increases in the U.S. since July 1," Bill Anderson, head of the Roche's drugs division, said on its conference call. "Overall in the world, our 10 percent sales growth in pharma was based on 15 percent volume growth and 5 percent average price declines across the portfolio." * The 10 Best Stocks to Buy for May Thanks to the company's newer cancer drugs like Tecentriq, it continues to deliver growth for shareholders. Vertex Pharmaceuticals (VRTX)Source: Shutterstock Although Vertex Pharmaceuticals (NASDAQ:VRTX) is best known for its cystic fibrosis drugs Kalydeco, Orkambi, and Symdeko, with 37,000 patients currently eligible to use them, it's also focusing on transformative medicines beyond cystic fibrosis for kidney disease, neuropathic pain and others. Of the 37,000 potential patients, about half are receiving treatment at the moment. By treating younger patients, it hopes to get that number up to 44,000, and using a triple combination regimen, it has its sight on 68,000 patients worldwide. Accomplishing this goal takes cash flow. To that end, Vertex has grown its operating cash flow over the past three years by 448% to $1.27 billion. That's starting from -$365 million in operating cash flow at the end of 2015. As a result, it's added $2.2 billion in cash to its balance sheet. From negative cash flow just three years ago, its free cash flow is now higher than $1.1 billion. In the first quarter ended March 31, Vertex increased free cash flow by 38% year over year to $307 million. Up just 8% year to date, the next eight months look ready to deliver a higher share price. Thermo Fisher Scientific (TMO)Source: Shutterstock Of the top ten holdings in PRHSX, Thermo Fisher Scientific (NYSE:TMO) has the second-best total return year to date, up 24%. Only Sage Therapeutics (NASDAQ:SAGE) has a better return. The fifth-largest holding in the fund portfolio, Thermo Fisher Scientific is a big buyer of its stock. Last September it announced a $2 billion share repurchase program. On May 2, it announced its first-quarter earnings report. While the 10-Q's not out yet, it did say it repurchased $750 million of its stock during the first quarter ended March 30 and increased its quarterly dividend by 12%. InvestorPlace contributor Josh Enomoto summed up why TMO is such a great stock."If you think about it, Thermo Fisher stands on an almost unassailable position. The biotech sector will never stop searching for the next big therapy," Josh stated last September while discussing the company's big buyback. "Of course, not all contenders are successful. But TMO doesn't have to be: they provide the equipment necessary for other companies to do their work." * 7 Stocks That Are Soaring This Earnings Season Why try to pick the next great biotech stock when you can own TMO and win no matter who it turns out to be? HCA Healthcare (HCA)Source: Shutterstock Not a large holding in T. Rowe Price's health sciences fund at a weighting of 1.9% (16th position), HCA Healthcare (NYSE:HCA) was first bought in 2011, so it's one of the fund's long-time holdings. HCA stock took a beating in April due to the Medicare-for-All scare that hurt many of the big healthcare stocks. It dropped 10%, its worst single-day performance since Trump's election victory in November 2016. However, the owner of 185 hospitals and 119 freestanding surgery centers in 21 states, has seen its stock recover most of those losses over the subsequent 7-10 days. "The market is ascribing an inordinately high probability that some form of Medicare-for-All proposal could become reality," Cowen analyst Charles Rhyee wrote in a note in April. "In our view, Medicare-for-All fails the Occam's razor test."For those who aren't Latin scholars, it means other, more straightforward options will likely be used to reform the healthcare system.Americans, especially Republican politicians, are so afraid of socialism, there's no way Medicare-for-All gets passed into legislation. As the population continues to age, hospitals will continue to experience significant demand, making HCA an excellent long-term buy. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Energy Stocks to Buy to Light Up Your Portfolio * 10 Vice Stocks to Spice Up Your Portfolio * 7 of the Best ETFs to Buy for a Slowing Economy Compare Brokers The post 7 Stocks to Buy From the T. Rowe Price Health Sciences Fund appeared first on InvestorPlace.
It’s time for the one-year update on a set of stocks that David Gardner picked to commemorate April the giraffe giving birth live on YouTube.
Health care stocks were the best sector in the Standard & Poor's 500-stock index in 2018, according to Yardeni Research. The sector's 4.7% gain last year isn't exactly eye-popping. But consider that utilities (+0.5%) were the only sector in the black, and that the index itself lost 6.2% ... and you realize just how impressive health care actually was.As we look ahead to 2019, economic storm clouds appear to be gathering. Although a recession is unlikely in the year ahead, UCLA economists estimate that GDP growth will shrink from 3% in 2018 to 2% in 2019 and finally 1% in 2020.Thus, in the potential absence of a good offense, it makes sense for investors to buy some defense in 2019. The best health care stocks can fit that bill. "Health care is a defensive growth sector that we think should have a growth upturn over the next five years or so," Saira Malik, head of global equities at Nuveen, told Fortune in November.With that in mind, here are 10 health care stocks to buy for 2019. SEE ALSO: 101 Best Dividend Stocks to Buy for 2019 and Beyond
It’s time for the one-year update on a set of stocks that David Gardner picked from his own portfolio, and the two-year update of his stocks for April the Giraffe.
Intuitive Surgical Inc (NASDAQ:ISRG) develops, manufactures and leases robotic surgery machines and accessories. Its da Vinci Surgical Systems brand is one of the biggest names in this fast-growing sector.Source: Jon Fingas via Flickr (Modified)The stock is off about 9% in the past month, and about half of that happened after it announced earnings last week. While ISRG revenues were in line with expectations, earnings missed by 3%. That was enough to send the stock sliding.But even after that hit, the stock still sports a trailing price-to-earnings ratio of 53, so it's cheaper now, but there's still plenty of faith left in its growth.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThat's apparent in its Q1 report, if you're interested in looking deeper into the numbers (which we are). First-quarter leases were down for the company, and that is what hamstrung earnings. But procedure growth was up by 18% and installations were around 235 units. ISRG Stock by the NumbersSo, let's break this down.ISRG sells robotic surgical machines that perform minimally invasive surgical (MIS) procedures as well as diagnostics. Basically, this is surgical procedures done with laparoscopy, which is a fair amount of common surgeries. And a surgeon is part of the team, but the da Vinci does a fair amount of the work.The machines are leased, so there's recurring income and there are also service contracts for parts and equipment and upkeep. These are the high-margin aspects of the business.These da Vinci machines had already performed more than 5 million MIS surgeries by 2017, and they're available in more than 4,400 hospitals worldwide. Because ISRG is one of the first pioneers in this sector, it has a significant competitive advantage since the barriers to entry are significant and it has built a reputation in a very conservative sector.Generally speaking, the medical profession is not one that jumps from shiny object to shiny object. Whether it is medicines, procedures or equipment, there is a lot to risk, especially in a surgical setting. Surgeons are not interested in getting sued for malpractice or losing hospital privileges.This is far from the dashcam videos of Tesla drivers throwing their car on Auto Pilot and letting it roll. Because ISRG stock has been around for more than two decades, it has the history and the relationships to show its value and reliability.There will certainly be competitors as tech advances and its potential market share may be challenged, but the potential market remains vast and can sustain a number of competitors without that eating into ISRG growth opportunities.And that is precisely where that procedure growth number comes in. That kind of growth shows that these machines are becoming accepted in their environments, which is a very bullish sign for the long term.My Portfolio Grader rates ISRG a B, and that means, any dip is a reason to buy.Louis Navellier is a renowned growth investor. He is the editor of four investing newsletters: Growth Investor, Breakthrough Stocks, Accelerated Profits and Platinum Growth. His most popular service, Growth Investor, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dividend Stocks That Could Double Over the Next Five Years * 6 S&P 500 Stocks Ready to Break Out * 5 Mining ETFs to Dig Into Compare Brokers The post Intuitive Surgical Is a Buy on This Dip appeared first on InvestorPlace.
The global demand for healthcare products and services will keep growing significantly. Here's your complete guide to finding the best healthcare stocks and ETFs.